Skip to content

A Study on Pain Relief Using Diclofenac Patches after Robot-Assisted Surgery for Kidney Cancer

Efficacy and Safety of Transdermal Diclofenac Sodium for Postoperative Analgesia after Robot-Assisted Surgery for Renal Malignancy: A Double-Blind, Randomized, Parallel-Group Study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs061250096
Enrollment
40
Registered
2026-03-02
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain after Robot-Assisted Surgery for Renal Malignancy Postoperative Pain

Interventions

On the day before surgery, apply two transdermal diclofenac sodium patches (each containing 75 mg of diclofenac sodium) to the back. After completion of the surgery, replace them with new patches of t

Sponsors

Tsutsumi Yasuo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing robot-assisted surgery for renal malignancy 2. Patients aged 18 years or older at the time of obtaining informed consent 3. Patients who are able to provide written informed consent for participation in this study

Exclusion criteria

Exclusion criteria: 1. Patients with active peptic ulcer 2. Patients with hematological disorders (aplastic anemia, hemolytic anemia, agranulocytosis, thrombocytopenia) 3. Patients with severe renal impairment 4. Patients with severe hepatic dysfunction 5. Patients with severe hypertension 6. Patients with congestive heart failure 7. Patients with a history of hypersensitivity to diclofenac sodium 8. Patients with aspirin-induced asthma or a history thereof 9. Patients receiving triamterene 10. Patients with acute or chronic pain due to underlying disease prior to surgery 11. Patients scheduled to receive PCEA, IV-PCA, or continuous nerve block anesthesia after surgery 12. Patients who routinely use opioid analgesics (regardless of the route of administration) or transdermal formulations of other analgesics 13. Patients with severe psychiatric disorders 14. Patients with a history of alcohol or drug abuse 15. Patients who are currently participating in another clinical study or intend to participate during this study 16. Patients judged by the principal investigator or sub-investigator to be clearly disadvantaged by participation in this study 17. Patients judged by the principal investigator or sub-investigator to make the conduct or evaluation of this study difficult by participation 18. The principal investigator or sub-investigator of this study, their family members, or employees of the participating institution 19. Women who are pregnant or may be pregnant 20. Patients undergoing bilateral robot-assisted surgery for renal malignancy

Design outcomes

Primary

MeasureTime frame
VAS score at postoperative day 1 (24 hours after surgery)

Secondary

MeasureTime frame
VAS score immediately after surgery Use of additional analgesics

Contacts

Public ContactYasuo Tsutsumi

Hiroshima university Hospital

masuika@hiroshima-u.ac.jp+81-82-257-5267

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026